date:Dec 04, 2012
ition business, while expanding its product offerings.
In Australia, Nestl's divesture commitments have satisfied the regulators - the company has agreed to sell an exclusive ten-year licence for Pfizer Nutrition's S-26/SMA brand portfolio to an independent purchaser.
In addition, following the end of the license period, Nestl has agreed not to re-enter the Australian market with Pfizer's brands for another ten years.
Nestl said that the regulatory approval process is underway in South Africa